Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma

CH Chung, J Li, CE Steuer, P Bhateja, M Johnson… - Clinical Cancer …, 2022 - AACR
Purpose: A phase II multi-institutional clinical trial was conducted to determine overall
survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous …
被引用次数：42 相关文章

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

CH Chung, J Li, CE Steuer… - Clinical Cancer …, 2022 - ohiostate.elsevierpure.com
Purpose: A phase II multi-institutional clinical trial was conducted to determine overall
survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous …

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

CH Chung, J Li, CE Steuer… - … : an official journal …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose A phase II multi-institutional clinical trial was conducted to determine overall
survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous …

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

CH Chung, J Li, CE Steuer, P Bhateja… - … Cancer Research: an …, 2022 - europepmc.org
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in
Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. - Abstract - Europe …

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

CH Chung, J Li, CE Steuer, P Bhateja, M Johnson… - Clinical Cancer …, 2022 - AACR
Purpose: A phase II multi-institutional clinical trial was conducted to determine overall
survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous …
[HTML] nih.gov

[HTML][HTML] Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma

CH Chung, J Li, CE Steuer, P Bhateja… - … cancer research: an …, 2022 - ncbi.nlm.nih.gov
Purpose: A phase II multi-institutional clinical trial was conducted to determine overall
survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous …